Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD 0.4850
+0.0050 (1.03%)
Aug 13, 2025, 4:13 PM AEST
Dimerix Company Description
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.
The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology.
Dimerix Limited is headquartered in Fitzroy, Australia.
Contact Details
Address: 425 Smith Street Fitzroy, 3065 Australia | |
| Phone | 1300 813 321 |
| Website | dimerix.com |
Stock Details
| Ticker Symbol | DXB |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000DXB7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. | Chief Executive Officer, MD and Director |
| Dr. David Everett Fuller BPharm, M.D., MBBS | Chief Medical Officer |
| Robert Shepherd | Chief Commercialisation Officer |
| Hamish George B.Com., C.A. | Chief Financial Officer and Company Secretary |
| Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor |